Literature DB >> 24429405

Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.

Aditi Sinha1, Jaya Bajpai1, Savita Saini1, Divya Bhatia1, Aarti Gupta1, Mamta Puraswani1, Amit K Dinda2, Sanjay K Agarwal3, Shailaja Sopory4, Ravindra M Pandey5, Pankaj Hari1, Arvind Bagga1.   

Abstract

In this prospective study, we measured serum levels of the soluble urokinase receptor (suPAR) in pediatric patients with nephrotic syndrome of various etiologies. Mean levels of suPAR were 3316 pg/ml in 99 patients with steroid-resistant focal segmental glomerulosclerosis and 3253 pg/ml in 117 patients with biopsy-proven minimal change disease, which were similar to that of 138 patients with steroid-sensitive nephrotic syndrome (3150 pg/ml) and 83 healthy controls (3021 pg/ml). Similar proportions of patients in each group had suPAR over 3000 pg/ml. Compared with controls, suPAR levels were significantly higher in patients with focal segmental glomerulosclerosis (FSGS) and estimated glomerular filtration rate (eGFR) under 30 ml/min per 1.73 m(2) (6365 pg/ml), congenital nephrotic syndrome (4398 pg/ml), and other proteinuric diseases with or without eGFR under 30 ml/min per 1.73 m(2) (5052 and 3875 pg/ml, respectively; both significant). There were no changes following therapy and during remission. Levels of suPAR significantly correlated in an inverse manner with eGFR (r=-0.36) and directly with C-reactive protein (r=0.20). The urinary suPAR-to-creatinine ratio significantly correlated with proteinuria (r=0.25) in 151 patients and controls. Using generalized estimating equations approach, serum suPAR significantly correlated with eGFR (coefficient=-13.75), age at sampling (2.72), and C-reactive protein (39.85). Thus, serum suPAR levels in nephrotic syndrome are similar to controls, and do not discriminate between FSGS, minimal change disease, or steroid-responsive illness.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24429405     DOI: 10.1038/ki.2013.546

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  54 in total

1.  C3a and suPAR drive versican V1 expression in tubular cells of focal segmental glomerulosclerosis.

Authors:  Runhong Han; Shuai Hu; Weisong Qin; Jinsong Shi; Qin Hou; Xia Wang; Xiaodong Xu; Minchao Zhang; Caihong Zeng; Zhihong Liu; Hao Bao
Journal:  JCI Insight       Date:  2019-04-04

2.  Successful treatment by mycophenolate mofetil in a patient with focal segmental glomerulosclerosis associated with posterior reversible encephalopathy syndrome.

Authors:  Masafumi Tenta; Haruhito Adam Uchida; Tomokazu Nunoue; Ryoko Umebayashi; Yuka Okuyama; Masashi Kitagawa; Yohei Maeshima; Hitoshi Sugiyama; Jun Wada
Journal:  CEN Case Rep       Date:  2014-12-30

3.  Serum suPAR levels are modulated by immunosuppressive therapy of minimal change nephrotic syndrome.

Authors:  Jutta Gellermann; Franz Schaefer; Uwe Querfeld
Journal:  Pediatr Nephrol       Date:  2014-08-17       Impact factor: 3.714

4.  Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children.

Authors:  Zhaoyang Peng; Jianhua Mao; Xuejun Chen; Fengqing Cai; Weizhong Gu; Haidong Fu; Huijun Shen; Jingjing Wang; Xia Jin; Xiujuan Zhu; Aimin Liu; Qiang Shu; Lizhong Du
Journal:  Pediatr Nephrol       Date:  2014-07-18       Impact factor: 3.714

5.  Reply: Measurement of serum suPAR is not ready for clinical use.

Authors:  Jeroen Deegens; Jack Wetzels
Journal:  Nat Rev Nephrol       Date:  2014-08-26       Impact factor: 28.314

6.  Soluble urokinase-type plasminogen activator receptor in FSGS: stirred but not shaken.

Authors:  Jochen Reiser; Harold Chapman
Journal:  J Am Soc Nephrol       Date:  2014-05-01       Impact factor: 10.121

7.  Mechanisms of Scarring in Focal Segmental Glomerulosclerosis.

Authors:  Jianyong Zhong; Jacob B Whitman; Hai-Chun Yang; Agnes B Fogo
Journal:  J Histochem Cytochem       Date:  2019-05-22       Impact factor: 2.479

8.  Urinary CD80 levels as a diagnostic biomarker of minimal change disease.

Authors:  Chen Ling; Xiaorong Liu; Ying Shen; Zhi Chen; Jianfeng Fan; Yeping Jiang; Qun Meng
Journal:  Pediatr Nephrol       Date:  2014-08-21       Impact factor: 3.714

Review 9.  Focal segmental glomerular sclerosis: do not overlook the role of immune response.

Authors:  Francesco Reggiani; Claudio Ponticelli
Journal:  J Nephrol       Date:  2016-02-20       Impact factor: 3.902

Review 10.  Podocyte-actin dynamics in health and disease.

Authors:  Luca Perico; Sara Conti; Ariela Benigni; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2016-08-30       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.